Ensysce Biosciences, Inc. (NASDAQ: ENSC) has initiated a pivotal Phase 3 study of PF614, its lead product candidate designed to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE